Literature DB >> 2157636

Inhibitors of the leukocyte superoxide generating oxidase: mechanisms of action and methods for their elucidation.

A R Cross1.   

Abstract

Oxygen radical production by phagocytic cells is currently receiving a great deal of attention as the role of radical damage is becoming apparent in inflammatory diseases, reperfusion injury, cancer, and aging. A large number of inhibitors of the superoxide generating oxidase are known, including standard and experimental anti-inflammatory and anti-rheumatic drugs, natural products, anaesthetics, tranquillizers and antibiotics, in addition to compounds used as experimental tools. The composition of the oxidase and the possible sites of inhibition of these compounds are discussed together with the possible mechanisms of activation of the oxidase and the effects these agents may have on these pathways. Use of these compounds has provided a great deal of information about the components and the nature of the activation processes involved in the stimulation of radical production by leukocytes, as well as pointing to possible targets for the production of novel anti-inflammatory agents. It is clear however that further understanding of the precise nature of the activation pathways and the extent of the involvement of leukocyte-derived oxygen radicals in disease processes will require more specific inhibitors than most of those currently available.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2157636     DOI: 10.1016/0891-5849(90)90147-b

Source DB:  PubMed          Journal:  Free Radic Biol Med        ISSN: 0891-5849            Impact factor:   7.376


  29 in total

1.  Evidence for functional interaction of plasma membrane electron transport, voltage-dependent anion channel and volume-regulated anion channel in frog aorta.

Authors:  Rashmi P Rao; J Prakasa Rao
Journal:  J Biosci       Date:  2010-12       Impact factor: 1.826

2.  Novel p47(phox)-related organizers regulate localized NADPH oxidase 1 (Nox1) activity.

Authors:  Davide Gianni; Begoña Diaz; Nicolas Taulet; Bruce Fowler; Sara A Courtneidge; Gary M Bokoch
Journal:  Sci Signal       Date:  2009-09-15       Impact factor: 8.192

3.  Interaction of rifalazil with oxidant-generating systems of human polymorphonuclear neutrophils.

Authors:  M T Labro; V Ollivier; C Babin-Chevaye
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

4.  The role of free radical scavengers, inhibitors of prostaglandin synthesis, and hypomethylating agents in reactivation of latent herpes simplex virus.

Authors:  S Sienko; A M Eis-Hübinger; K E Schneweis
Journal:  Med Microbiol Immunol       Date:  1991       Impact factor: 3.402

Review 5.  Nox Inhibitors & Therapies: Rational Design of Peptidic and Small Molecule Inhibitors.

Authors:  M Eugenia Cifuentes-Pagano; Daniel N Meijles; Patrick J Pagano
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

6.  Accelerated calcium influx and hyperactivation of neutrophils in chronic granulomatous disease.

Authors:  G R Tintinger; A J Theron; H C Steel; R Anderson
Journal:  Clin Exp Immunol       Date:  2001-02       Impact factor: 4.330

7.  Synergistic effects among oxidants, membrane-damaging agents, fatty acids, proteinases, and xenobiotics: killing of epithelial cells and release of arachidonic acid.

Authors:  I Ginsburg; R Kohen
Journal:  Inflammation       Date:  1995-02       Impact factor: 4.092

8.  The role of monoamine metabolism in oxidative glutamate toxicity.

Authors:  P Maher; J B Davis
Journal:  J Neurosci       Date:  1996-10-15       Impact factor: 6.167

9.  The molecular basis for adhesion-mediated suppression of reactive oxygen species generation by human neutrophils.

Authors:  Tieming Zhao; Valerie Benard; Benjamin P Bohl; Gary M Bokoch
Journal:  J Clin Invest       Date:  2003-12       Impact factor: 14.808

Review 10.  Chemical and molecular mechanisms of antioxidants: experimental approaches and model systems.

Authors:  Jian-Ming Lü; Peter H Lin; Qizhi Yao; Changyi Chen
Journal:  J Cell Mol Med       Date:  2009-09-14       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.